Lisinopril 5mg/5ml oral suspension
Requires a prescription from a doctor or prescriber
Hypertension and heart failure
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Lisinopril
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Lisinopril
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Carace brand family (generic: Lisinopril)
MHRA licensed products
View all licensed products for Lisinopril on the MHRA register
WHO defined daily dose (DDD)
10 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Lisinopril
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
39 found
Half-life
12.6h
Mechanism
Angiotensin II constricts coronary blood vessels and is positively inotropic, wh…
Food interactions
4 warnings
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
6-60%
[A184754][L8384][L8387][L8390]…
Half-life
12.6h
[A184754]
Protein binding
[L8384][L8387][L8390]
Volume of distribution
124L
[A184781]
Metabolism
[L8384][L8387][L8390]
Elimination
[L8384][L8387][L8390]
Clearance
10L/h
[L8384][L8387]…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Lisinopril was granted FDA approval on 29 December 1987.[L8384]
[L8384][L8387]
A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.
[L8390]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1318 interactions
[L8399]
The oral LDLO in women is 1200µg/kg/16D and in men is 43mg/kg/43W.
[L8399]
Patients experiencing an overdose of lisinopril may present with hypotension.
[L8384][L8387][L8390]
Patients should be treated with intravenous saline to restore blood pressure.
[L8384][L8387][L8390]
Lisinopril can be removed from the blood by hemodialysis due to it not being protein bound.
[L8384][L8387][L8390]
Lisinopril is an angiotensin converting enzyme inhibitor (ACEI), preventing the conversion of angiotensin I to angiotensin II.[A184781][A184808] This action prevents myocyte hypertrophy and vascular smooth muscle cell proliferation seen in untreated patients.[A184808] Increased levels of bradykinin also exhibit vasodilating effects for patients taking ACEIs.[A184808] Lisinopril also inhibits renin's conversion of angiotensin to angiotensin I.[A184817]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A184754][L8384][L8387][L8390]
Lisinopril reaches a Cmax of 58ng/mL with a Tmax of 6-8h.
[A184754]
Lisinopril's absorption is not affected by food.
[A184754]
[A184754]
[L8384][L8387][L8390]
[A184781]
[L8384][L8387][L8390]
[L8384][L8387][L8390]
[L8384][L8387]
The mean renal clearance of lisinopril in healthy adult males is 121mL/min.
[A184754]
Proteins and enzymes this drug interacts with in the body
PMID:15615692 PMID:20826823 PMID:2558109 PMID:4322742 PMID:7523412 PMID:7683654
Composed of two similar catalytic domains, each possessing a functional active site, with different selectivity for substrates .
PMID:10913258 PMID:1320019 PMID:1851160 PMID:19773553 PMID:7683654 PMID:7876104
Plays a major role in the angiotensin-renin system that regulates blood pressure and sodium retention by the kidney by converting angiotensin I to angiotensin II, resulting in an increase of the vasoconstrictor activity of angiotensin .
PMID:11432860 PMID:1851160 PMID:19773553 PMID:23056909 PMID:4322742
Also able to inactivate bradykinin, a potent vasodilator, and therefore enhance the blood pressure response .
PMID:15615692 PMID:2558109 PMID:4322742 PMID:6055465 PMID:6270633 PMID:7683654
Acts as a regulator of synaptic transmission by mediating cleavage of neuropeptide hormones, such as substance P, neurotensin or enkephalins .
PMID:15615692 PMID:6208535 PMID:6270633 PMID:656131
Catalyzes degradation of different enkephalin neuropeptides (Met-enkephalin, Leu-enkephalin, Met-enkephalin-Arg-Phe and possibly Met-enkephalin-Arg-Gly-Leu) .
PMID:2982830 PMID:6270633 PMID:656131
Acts as a regulator of synaptic plasticity in the nucleus accumbens of the brain by mediating cleavage of Met-enkephalin-Arg-Phe, a strong ligand of Mu-type opioid receptor OPRM1, into Met-enkephalin (By similarity). Met-enkephalin-Arg-Phe cleavage by ACE decreases activation of OPRM1, leading to long-term synaptic potentiation of glutamate release (By similarity). Also acts as a regulator of hematopoietic stem cell differentiation by mediating degradation of hemoregulatory peptide N-acetyl-SDKP (AcSDKP) .
PMID:26403559 PMID:7876104 PMID:8257427 PMID:8609242
Acts as a regulator of cannabinoid signaling pathway by mediating degradation of hemopressin, an antagonist peptide of the cannabinoid receptor CNR1 .
PMID:18077343
Involved in amyloid-beta metabolism by catalyzing degradation of Amyloid-beta protein 40 and Amyloid-beta protein 42 peptides, thereby preventing plaque formation .
PMID:11604391 PMID:16154999 PMID:19773553
Catalyzes cleavage of cholecystokinin (maturation of Cholecystokinin-8 and Cholecystokinin-5) and Gonadoliberin-1 (both maturation and degradation) hormones .
PMID:10336644 PMID:2983326 PMID:7683654 PMID:9371719
Degradation of hemoregulatory peptide N-acetyl-SDKP (AcSDKP) and amyloid-beta proteins is mediated by the N-terminal catalytic domain, while angiotensin I and cholecystokinin cleavage is mediated by the C-terminal catalytic region PMID:10336644 PMID:19773553 PMID:7876104
Proteins that transport this drug across cell membranes
PMID:15521010 PMID:18367661 PMID:19685173 PMID:26320580 PMID:7896779 PMID:8914574 PMID:9835627
Primarily responsible for the absorption of dietary di- and tripeptides from the small intestinal lumen (By similarity). Mediates transepithelial transport of muramyl and N-formylated bacterial dipeptides contributing to recognition of pathogenic bacteria by the mucosal immune system PMID:15521010 PMID:9835627
PMID:16434549 PMID:18367661 PMID:7756356
Transports neutral and anionic dipeptides with a proton to peptide stoichiometry of 2:1 or 3:1 (By similarity). In kidney, involved in the absorption of circulating di- and tripeptides from the glomerular filtrate .
PMID:7756356
Can also transport beta-lactam antibiotics, such as the aminocephalosporin cefadroxil, and other antiviral and anticancer drugs .
PMID:16434549
Transports the dipeptide-like aminopeptidase inhibitor bestatin (By similarity). Also able to transport carnosine .
PMID:31073693
Involved in innate immunity by promoting the detection of microbial pathogens by NOD-like receptors (NLRs) (By similarity).
Mediates transport of bacterial peptidoglycans across the plasma membrane or, in macrophages, the phagosome membrane: catalyzes the transport of certain bacterial peptidoglycans, such as muramyl dipeptide (MDP), the NOD2 ligand PMID:20406817
Involved compounds
ATC C09BA03
ATC C10BX07
ATC C09AA03
ATC C09BB03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Lisinopril
Additional database identifiers
Drugs Product Database (DPD)
1253
ChemSpider
4514933
BindingDB
50367879
PDB
LPR
ZINC
ZINC000003812863
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2707
GenAtlas
ACE
GeneCards
ACE
GenBank Gene Database
J04144
GenBank Protein Database
178286
Guide to Pharmacology
1613
UniProt Accession
ACE_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9958
GenAtlas
REN
GeneCards
REN
GenBank Gene Database
L00073
GenBank Protein Database
190994
Guide to Pharmacology
2413
UniProt Accession
RENI_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10920
GenAtlas
SLC15A1
GeneCards
SLC15A1
GenBank Gene Database
U13173
GenBank Protein Database
773588
Guide to Pharmacology
984
UniProt Accession
S15A1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10921
GenAtlas
SLC15A2
GeneCards
SLC15A2
GenBank Gene Database
S78203
GenBank Protein Database
999213
Guide to Pharmacology
985
UniProt Accession
S15A2_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
12 active patents
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: